LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
Rhea-AI Summary
LIXTE (Nasdaq: LIXT) named Sidney Braun CEO of its Liora Technologies Europe Ltd. subsidiary effective Feb 18, 2026. Braun has more than two decades of healthcare operational and advisory experience and helped create Liora and facilitate LIXTE’s acquisition of Liora assets in November 2025.
Liora develops the proprietary LiGHT System, an electronically controlled proton therapy platform the company says may offer advantages for treating tumors and support a future recurring revenue model for LIXTE.
AI-generated analysis. Not financial advice.
Positive
- Acquisition of Liora assets closed in November 2025
- Named Sidney Braun as CEO of Liora with 20+ years' experience
- Strategic focus on commercializing the LiGHT System proton therapy
- Company signals pursuit of a recurring revenue model via Liora
Negative
- No regulatory approval or clearance for the LiGHT System disclosed
- No commercialization timeline or financial impact metrics provided
News Market Reaction – LIXT
On the day this news was published, LIXT gained 1.32%, reflecting a mild positive market reaction. This price movement added approximately $247K to the company's valuation, bringing the market cap to $18.94M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: QTTB up 8.91%, BOLD up 1.77%, while PPCB down 7.99%, ALLR down 2.35%, AKTX down 1.21%. Momentum scanner only flags ICU up 3.31%, suggesting stock-specific rather than sector-wide drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | Health summit sponsorship | Positive | +4.0% | Sponsoring De La Soul-led Good Health Summit on Feb 19, 2026. |
| Jan 20 | Conference participation | Neutral | -8.4% | Attending DealFlow Discovery Conference with investor meetings scheduled. |
| Dec 23 | Trial expansion | Positive | -1.9% | Doubling enrollment in ovarian clear cell cancer trial of LB-100 combo. |
| Dec 18 | Equity offering | Negative | -1.0% | Registered direct offering raising about $4.3M via units and warrants. |
| Dec 08 | Strategy shift | Positive | +7.2% | Outlining oncology platform strategy including LiGHT System radiotherapy. |
News on strategic initiatives and platforms has sometimes led to positive moves, while financings and conference appearances have seen mixed or negative reactions.
Over the last few months, LIXTE has combined strategic repositioning with capital raises and clinical progress. On December 8, 2025, it highlighted a broader oncology platform strategy around LB-100 and the LiGHT System, which coincided with a 7.16% gain. A $4.3 million offering on December 18, 2025 saw a modest -1.01% move. Expansion of an ovarian cancer trial on December 23, 2025 and recent conference- and summit-related news produced mixed price reactions. Today’s leadership appointment at Liora fits into this ongoing platform build-out.
Market Pulse Summary
This announcement reinforces LIXTE’s strategy of integrating Liora’s LiGHT System proton radiotherapy platform into its oncology vision by installing an experienced healthcare operator as Liora’s CEO. It follows prior disclosures about acquiring Liora and broadening beyond a single-asset model. Investors may watch how Braun advances commercialization plans, supports recurring revenue ambitions, and complements ongoing clinical work with LB-100, especially given recent financings and the company’s focus on long-term value creation.
Key Terms
biologic drug medical
immune-mediated inflammatory diseases medical
radiotherapy medical
proton therapy medical
proton therapy systems medical
tumors medical
AI-generated analysis. Not financial advice.
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company’s Liora Technologies Europe Ltd. subsidiary (“Liora”).
A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE’s acquisition of Liora’s assets in November 2025 from Orbit Capital, Inc.
Over his career, Braun played a key role in building an infusion network for the biologic drug Remicade, which was approved to treat several immune-mediated inflammatory diseases. He also created a physician network in Canada that was sold to Toronto-based AIM Health Group. Braun is multi-lingual and holds degrees in economics and business administration from Fordham University.
“The appointment of Sidney Braun as CEO of Liora is in keeping with our plan to bring Liora’s LiGHT System technology to the forefront of modern cancer treatment and eventually enable LIXTE to pursue a recurring revenue model,” said Geordan Pursglove, CEO of LIXTE. “We welcome Sidney to the LIXTE family and are confident of the contributions he will make to our organization and to advancing and scaling an important technology in cancer treatment.”
“Leadership in breakthrough medical technology is about building viable life-changing systems,” added Braun. “I step into my new role at Liora fully committed to fostering further development in the radiotherapy segment of cancer care to achieve positive patient outcomes and long-term value for LIXTE’s shareholders.”
Liora is pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. The Company’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at www.lixte.com.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements, also including but not limited to, pursuing a recurring revenue model through the Company’s acquired LiGHT system, are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For more information about LIXTE, contact:
info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
